Injective News: Nasdaq Approves INJC Listing for Staked INJ ETF
This Injective News update is simple: Nasdaq has approved the listing of the Canary Staked INJ ETF.
It is expected to trade under the ticker INJC, as a new SEC filing shows.
The fund would hold INJ and stake most of it to earn rewards. Approval to list is not the same as a start of trading, and the sources reviewed show no confirmed trading date.
What Does the Nasdaq Approval for INJC Mean?
The filing says the listing application for the ETF shares was filed with Nasdaq and approved. The shares are common shares of a Delaware trust, and Canary Capital Group acts as the sponsor. The ticker INJC is named in the fund’s prospectus. In plain words, the exchange has said the shares can be listed, but nobody can buy them until trading starts.
Can You Buy INJC Today?
For Injective News readers who are asking this, the answer is not yet, as far as the public record shows. A listing approval is one step on the road to launch, and the fund still has to begin trading.
No start date has been named in the filings or posts reviewed. Any date you see online should be treated as a guess until the sponsor or Nasdaq confirms it.
How Does the Canary Staked INJ ETF Work?
The fund at the center of this Injective News story aims to give investors exposure to the price of INJ without making them hold the coin in a wallet.
The sponsor expects to stake at least 90% of the fund’s INJ under normal conditions, and a small part may be kept aside to meet redemptions.
Staking is a way to earn extra INJ by helping to run the network, and the filing calls it a secondary goal. A bank named BitGo acts as the custodian that holds the INJ for the fund.
INJC ETF Fees, Staking Rewards, and Seed Funding
The amended filing lists a sponsor fee of 1.10% a year. Up to 30% of the staking rewards can also go to service providers. The Injective Foundation plans to buy up to $15 million of shares, and it would pay for them in INJ.
For anyone who follows Injective News, these costs matter, because a fund that stakes for you also takes a share of what the staking earns.
What Are the Risks Behind This Injective News?
Every crypto fund carries risk, and this one is no different. The price of INJ can swing a lot, and staking rewards do not protect you from a sharp fall. Staked coins are also locked for a set time before they can be freed.
That can make it harder to meet a rush of sell orders. The fund will not be registered under the Investment Company Act, so some of the usual investor protections do not apply.
What Happens Next for INJC Investors?
Three things are worth watching in the coming days. The first is a confirmed date for the start of trading, the second is any change to the final prospectus, and the third is news from Injective itself.
Until a date is set, any plan to buy INJC is only a guess. Follow the Injective account on X and check the SEC site for the latest crypto news before you act.
This Injective News story is still moving, so every detail here could change as new filings arrive.
YMYL Disclaimer: This article is for information only and is not financial, investment, or trading advice. Details come from public SEC filings and Injective posts and may change. Crypto assets are volatile, so always check official sources first.
